Tirzepatide 7.5mg
Tirzepatide 7.5mg mid-range research vial — bridging dose for extended-phase incretin pathway research.
Consulta al por Mayor
10+ viales · OEM / Marca Privada · Envío en Cadena de Frío
Cotización de Fábrica por WhatsAppPrecios por Volumen
Descuentos aplicados mediante cotización por WhatsApp para consultas calificadas de investigación / clínicas.
Tirzepatide 7.5mg sits between the 5mg early-escalation and 15mg therapeutic strengths, providing a bridging concentration for research labs studying dose-response curves. The lyophilized format and ≥99% HPLC + MS verified purity support both in-vitro receptor binding assays and longitudinal metabolic models.
Key Benefits
- Mid-range bridging dose between 5mg and 15mg
- ≥99% HPLC + MS verified purity
- Dual GIP/GLP-1 receptor agonist mechanism
- Useful for dose-response curve plotting
- Batch-matched COA with every vial
- Cold-chain shipping preserves integrity
Scientific Background
At 7.5mg, both GIP and GLP-1 receptor pathways approach near-maximal activation in published research models without exceeding the typical therapeutic ceiling observed in 15mg protocols. This makes 7.5mg an analytically useful concentration for studying the transition zone between sub-therapeutic and maximal response.
Educational Display Only
This product information is for educational purposes. Always consult licensed healthcare providers for personalized medical advice.
Frequently Asked Questions
Related Products
NAD+
Cellular health supplement supporting NAD+ levels, a crucial coenzyme involved in energy metabolism and cellular repair processes.
Available: 100mg, 200mg, 500mg
Semaglutide
GLP-1 receptor agonist for metabolic health optimization, supporting healthy weight management and glucose metabolism.
Available: 0.25mg, 0.5mg, 1mg
Tirzepatide
Dual GIP/GLP-1 receptor agonist representing the next generation of metabolic health therapeutics.
Available: 2.5mg, 5mg, 7.5mg, 15mg, 20mg, 30mg